Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019-Reference-Cited by-同舟云学术

Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019

Published:2022-04 Issue: Volume:Volume 14 Page:189-203
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Bilitou Aikaterini,Were John^ORCID,Farrer Archie,Rabe Adrian,Ming Simon Wan Yau,Haq Inaam,Dunton Kyle

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference34 articles.

1. British Heart Foundation. UK factsheet; 2021. Available from: www.bhf.org.uk/what-we-do/our-research/heart-statistics. Accessed May 3, 2021.

2. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

3. European Heart Network. European Cardiovascular Disease Statistics: 2017 Edition. Brussels, Belgium: European Heart Network; 2017.

4. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk

5. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of patients seeking national health service (NHS) care for Achilles tendinopathy: A service evaluation of 573 patients;Musculoskeletal Science and Practice;2024-11

2. A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets;Drugs in Context;2024-08-08

3. Prevalence and distributions of severely elevated low-density lipoprotein cholesterol (LDL-c) according to age, gender and clinic location among patients in the Malaysian primary care;Clinical Epidemiology and Global Health;2024-05

4. Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance;Pharmaceuticals;2024-03-11

5. Are We Using Ezetimibe As Much As We Should?;Biomarker Insights;2024-01